Drug intelligence / Profile preview

IDB003

Development stage: Unknown
Lead developer: IDBiologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IDB003 is a preclinical, ultra-potent human monoclonal antibody developed by IDBiologics for the treatment and prevention of COVID-19. It was discovered at the Vanderbilt Vaccine Center (VVC) in Dr. James Crowe's lab from B cells of recovered COVID-19 patients and exclusively licensed by IDBiologics from Vanderbilt University Medical Center (VUMC). The antibody targets the SARS-CoV-2 Spike protein. IDBiologics planned to initiate a Phase 1 clinical trial in the third quarter of 2020.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on IDB003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDB003.

Explore the full profile